Nissen champions a lower-cost trial design for cholesterol med

Steven Nissen (photo), the Cleveland Clinic's high-profile chief of cardiology, has designed a clinical trial of a new cholesterol medication advanced by Sweden's Karo Bio that he says can dramatically reduce the cost of late-stage research while satisfying the FDA's tough standards for safety and efficacy data in the field. "What we are trying to do is look for a strategy that allows the company to move forward in a deliberative fashion to develop the data they need without costing...